Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues

Journal of Medicinal Chemistry

Volumn 57, Issue 24, 2014, Pages 10464-10475

  Riley, Andrew P ^a   Groer, Chad E ^a   Young, David ^b   Ewald, Amy W ^b   Kivell, Bronwyn M ^b   Prisinzano, Thomas E ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; FURAN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; METHYL 9 ACETOXY 2 (2 CYANOFURAN 3 YL) 6A,10B DIMETHYL 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMEN 7 CARBOXYLATE; METHYL 9 ACETOXY 2 (2 ETHYLFURAN 3 YL) 6A,10B DIMETHYL 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 2 (2 FORMYLFURAN 3 YL) 6A,10B DIMETHYL 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMEN 7 CARBOXYLATE; METHYL 9 ACETOXY 2 (2,5 DIMETHYLFURAN 3 YL) 6A,10B DIMETHYL 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMEN 7 CARBOXYLATE; METHYL 9 ACETOXY 2 [2 (2 AMINOPHENYL)FURAN 3 YL] 6A,10B DIMETHYL 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 2 [2 (2 NITROPHENYL)FURAN 3 YL] 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 2 [2 (3 NITROPHENYL)FURAN 3 YL] 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 2 [2 (4 NITROPHENYL)FURAN 3 YL] 4,10 DIOXODODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 4,10 DIOXO 2 [2 (3 AMINOPHENYLFURAN 3 YL) DODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 4,10 DIOXO 2 [2 (4 AMINOPHENYLFURAN 3 YL) DODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; METHYL 9 ACETOXY 6A,10B DIMETHYL 4,10 DIOXO 2 [5 (TRIFLUOROMETHYLFURAN 3 YL) DODECAHYDRO 1H BENZO[F]ISOCHROMENE 7 CARBOXYLATE; SALVINORIN A; SALVINORIN A DERIVATIVE; UNCLASSIFIED DRUG; CLERODANE DERIVATIVE; FURAN DERIVATIVE; PSYCHEDELIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL LINE; DRUG RECEPTOR BINDING; DRUG SEEKING BEHAVIOR; DRUG SYNTHESIS; FEMALE; HETERONUCLEAR MULTIPLE BOND CORRELATION; IN VITRO STUDY; LOCOMOTION; NONHUMAN; RAT; SONOGASHIRA REACTION; SUBSTITUTION REACTION; AGONISTS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; DRUG EFFECTS; MALE; MOTOR ACTIVITY; SALVIA; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETULUS; DITERPENES, CLERODANE; FURANS; HALLUCINOGENS; MALE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SALVIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920109429     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501521d     Document Type: Article

References (65)

1. Mansour, A.; Fox, C. A.; Burke, S.; Meng, F.; Thompson, R. C.; Akil, H.; Watson, S. J. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study J. Compar. Neurol. 1994, 350, 412-438
2. Mansour, A.; Fox, C. A.; Meng, F.; Akil, H.; Watson, S. J. κ1 Receptor mRNA distribution in the rat CNS: Comparison to κ receptor binding and prodynorphin mRNA Mol. Cell. Neurosci. 1994, 5, 124-144
3. Minami, M.; Satoh, M. Molecular biology of the opioid receptors: Structures, functions and distributions Neurosci. Res. 1995, 23, 121-145
4. Knoll, A. T.; Carlezon, W. A., Jr. Dynorphin, stress, and depression Brain Res. 2010, 1314, 56-73
5. Preti, A. New developments in the pharmacotherapy of cocaine abuse Addict. Biol. 2007, 12, 133-151
6. Vocci, F. J.; Acri, J.; Elkashef, A. Medication development for addictive disorders: The state of the science Am. J. Psychiatry 2005, 162, 1432-1440
7. Prisinzano, T. E.; Tidgewell, K.; Harding, W. W. Kappa opioids as potential treatments for stimulant dependence AAPS J. 2005, 7, E592-599
8. Prisinzano, T. E. Natural products as tools for neuroscience: Discovery and development of novel agents to treat drug abuse J. Nat. Prod. 2009, 72, 581-587
9. Prevatt-Smith, K. M.; Prisinzano, T. E. New therapeutic potential for psychoactive natural products Nat. Prod. Rep. 2010, 27, 23-31
10. Gullapalli, S.; Ramarao, P. L-type Ca2+ channel modulation by dihydropyridines potentiates κ-opioid receptor agonist induced acute analgesia and inhibits development of tolerance in rats Neuropharmacology 2002, 42, 467-475
11. Kivell, B.; Prisinzano, T. E. Kappa opioids and the modulation of pain Psychopharmacology (Berlin, Ger.) 2010, 210, 109-119
12. Glick, S. D.; Maisonneuve, I. M.; Raucci, J.; Archer, S. Kappa opioid inhibition of morphine and cocaine self-administration in rats Brain Res. 1995, 681, 147-152
13. Negus, S. S.; Mello, N. K.; Portoghese, P. S.; Lin, C.-E. Effects of kappa opioids on cocaine self-administration by rhesus monkeys J. Pharmacol. Exp. Ther. 1997, 282, 44-55
14. Schenk, S.; Partridge, B.; Shippenberg, T. S. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking Psychopharmacology 1999, 144, 339-346
15. Schenk, S.; Partridge, B.; Shippenberg, T. S. Reinstatement of extinguished drug-taking behavior in rats: Effect of the kappa-opioid receptor agonist, U69593 Psychopharmacology 2000, 151, 85-90
16. Prevatt-Smith, K. M.; Lovell, K. M.; Simpson, D. S.; Day, V. W.; Douglas, J. T.; Bosch, P.; Dersch, C. M.; Rothman, R. B.; Kivell, B.; Prisinzano, T. E. Potential drug abuse therapeutics derived from the hallucinogenic natural product salvinorin A MedChemComm 2011, 2, 1217-1222
17. Land, B. B.; Bruchas, M. R.; Lemos, J. C.; Xu, M.; Melief, E. J.; Chavkin, C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system J. Neurosci. 2008, 28, 407-414
18. Mello, N. K.; Negus, S. S. Interactions between kappa opioid agonists and cocaine. Preclinical studies Ann. N. Y. Acad. Sci. 2000, 909, 104-132
19. Pfeiffer, A.; Brantl, V.; Herz, A.; Emrich, H. M. Psychotomimesis mediated by kappa opiate receptors Science 1986, 233, 774-776
20. Vonvoigtlander, P. F.; Lahti, R. A.; Ludens, J. H. U-50,488: A selective and structurally novel non-Mu (kappa) opioid agonist J. Pharmacol. Exp. Ther. 1983, 224, 7-12
21. Metcalf, M. D.; Coop, A. Kappa opioid antagonists: Past successes and future prospects AAPS J. 2005, 7, E704-E722
22. Broadbear, J.; Stevens Negus, S.; Butelman, E.; de Costa, B.; Woods, J. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay Psychopharmacology 1994, 115, 311-319
23. Ko, M. C. H.; Willmont, K. J.; Lee, H.; Flory, G. S.; Woods, J. H. Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys Brain Res. 2003, 982, 38-44
24. Reiter, E.; Ahn, S.; Shukla, A. K.; Lefkowitz, R. J. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Annu. Rev. Pharmacol. Toxicol. 2012, 52, 179-197
25. Seifert, R. Functional selectivity of G-protein-coupled receptors: From recombinant systems to native human cells Biochem. Pharmacol. 2013, 86, 853-861
26. Goicoechea, C.; Ormazábal, M. J.; Abalo, R.; Alfaro, M. J.; Martín, M. I. Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice Neurosci. Lett. 1999, 273, 175-178
27. Bruchas, M. R.; Land, B. B.; Aita, M.; Xu, M.; Barot, S. K.; Li, S.; Chavkin, C. Stress-induced p38 mitogen-activated protein kinase activation mediates κ-opioid-dependent dysphoria J. Neurosci. 2007, 27, 11614-11623
28. Bruchas, M. R.; Macey, T. A.; Lowe, J. D.; Chavkin, C. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes J. Biol. Chem. 2006, 281, 18081-18089
29. Spinella, M. The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain, and Behavior; MIT Press: Cambridge, MA, 2001.
30. Prisinzano, T. E. Neoclerodanes as atypical opioid receptor ligands J. Med. Chem. 2013, 56, 3435-3443
31. Calixto, J. B.; Scheidt, C.; Otuki, M.; Santos, A. R. Biological activity of plant extracts: Novel analgesic drugs Expert Opin. Emerging Drugs 2001, 6, 261-279
32. Waldhoer, M.; Bartlett, S. E.; Whistler, J. L. Opioid receptors Annu. Rev. Biochem. 2004, 73, 953-990
33. Di Marzo, V. Endocannabinoids: Synthesis and degradation Rev. Physiol. Biochem. Pharmacol. 2008, 160, 1-24
34. Butler, M. S. Natural products to drugs: Natural product derived compounds in clinical trials Nat. Prod. Rep. 2005, 22, 162-195
35. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981 to 2010 J. Nat. Prod. 2012, 75, 311-335
36. Cragg, G. M.; Newman, D. J. Natural products: A continuing source of novel drug leads Biochim. Biophys. Acta 2013, 1830, 3670-3695
37. Ortega, A.; Blount, J. F.; Manchand, P. S. Salvinorin, a new trans-neoclerodane diterpene from Salvia-divinorum (Labiatae) J. Chem. Soc., Perkin Trans. 1982, 1, 2505-2508
38. Valdes, L. J., III; Butler, W. M.; Hatfield, G. M.; Paul, A. G.; Koreeda, M. Divinorin A, a psychotropic terpenoid, and divinorin B from the hallucinogenic mexican mint Salvia divinorum J. Org. Chem. 1984, 49, 4716-4720
39. Valdes, L. J., III Salvia divinorum and the unique diterpene hallucinogen, salvinorin (divinorin) A J. Psychoact. Drugs 1994, 26, 277-283
40. Lange, J. E.; Reed, M. B.; Ketchie Croff, J. M.; Clapp, J. D. College student use of Salvia divinorum Drug Alcohol Depend. 2008, 94, 263-266
41. Siebert, D. J. Salvia divinorum and salvinorin A: New pharmacologic findings J. Ethnopharmacol. 1994, 43, 53-56
42. Roth, B. L.; Baner, K.; Westkaemper, R.; Siebert, D.; Rice, K. C.; Steinberg, S.; Ernsberger, P.; Rothman, R. B. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 11934-11939
43. Wang, Y.; Tang, K.; Inan, S.; Siebert, D.; Holzgrabe, U.; Lee, D. Y. W.; Huang, P.; Li, J.-G.; Cowan, A.; Liu-Chen, L.-Y. Comparison of pharmacological activities of three distinct κ ligands (salvinorin A, TRK-820 and 3FLB) on κ opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo J. Pharmacol. Exp. Ther. 2005, 312, 220-230
44. McCurdy, C. R.; Prisinzano, T. E. Opioid receptor ligands. In Burger's Medicinal Chemistry, Drug Discovery, and Development, 7 th ed.; Abraham, D. J.; Rotella, D. P., Eds.; John Wiley & Sons, Inc.: New York, 2010; Vol. 8, pp 569-735.
45. Rees, D. C.; Hunter, J. C. In Comprehensive Medicinal Chemistry; Emmet, J. C., Ed.; Pergamon: New York, 1990; pp 805-846.
46. Yan, F.; Roth, B. L. Salvinorin A: A novel and highly selective kappa-opioid receptor agonist Life Sci. 2004, 75, 2615-2619
47. Kane, B. E.; McCurdy, C. R.; Ferguson, D. M. Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor J. Med. Chem. 2008, 51, 1824-1830
48. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Liu, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Structure of the human kappa-opioid receptor in complex with JDTic Nature 2012, 485, 327-332
49. Polepally, P. R.; Huben, K.; Vardy, E.; Setola, V.; Mosier, P. D.; Roth, B. L.; Zjawiony, J. K. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor Eur. J. Med. Chem. 2014, 85, 818-829
50. Groer, C. E.; Tidgewell, K.; Moyer, R. A.; Harding, W. W.; Rothman, R. B.; Prisinzano, T. E.; Bohn, L. M. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization Mol. Pharmacol. 2007, 71, 549-557
51. Cunningham, C. W.; Rothman, R. B.; Prisinzano, T. E. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A Pharmacol. Rev. 2011, 63, 316-347
52. Vardy, E.; Mosier, P. D.; Frankowski, K. J.; Wu, H.; Katritch, V.; Westkaemper, R. B.; Aubé, J.; Stevens, R. C.; Roth, B. L. Chemotype-selective modes of action of κ-opioid receptor agonists J. Biol. Chem. 2013, 288, 34470-34483
53. Wilson, W. C.; Simon, J.; Garst, J. E. The effects of selected bulky substituents on the pulmonary toxicity of 3-furyl ketones in mice J. Anim. Sci. 1990, 68, 1072-1076
54. Riley, A. P.; Day, V. W.; Navarro, H. A.; Prisinzano, T. E. Palladium-catalyzed transformations of salvinorin A, a neoclerodane diterpene from Salvia divinorum Org. Lett. 2013, 15, 5936-5939
55. Molander, G. A.; Katona, B. W.; Machrouhi, F. Development of the Suzuki-Miyaura cross-coupling reaction: Use of air-stable potassium alkynyltrifluoroborates in aryl alkynylations J. Org. Chem. 2002, 67, 8416-8423
56. 3]-salvinorin A Bioorg. Med. Chem. Lett. 2004, 14, 5099-5102
57. Béguin, C.; Duncan, K. K.; Munro, T. A.; Ho, D. M.; Xu, W.; Liu-Chen, L.-Y.; Carlezon, W. A., Jr.; Cohen, B. M. Modification of the furan ring of salvinorin A: Identification of a selective partial agonist at the kappa opioid receptor Bioorg. Med. Chem. 2009, 17, 1370-1380
58. Nagib, D. A.; MacMillan, D. W. C. Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis Nature 2011, 480, 224-228
59. Munro, T. A.; Xu, W.; Ho, D. M.; Liu-Chen, L.-Y.; Cohen, B. M. Studies toward bivalent κ opioids derived from salvinorin A: Heteromethylation of the furan ring reduces affinity Beilstein J. Org. Chem. 2013, 9, 2916-2924
60. Leung, C. S.; Leung, S. S. F.; Tirado-Rives, J.; Jorgensen, W. L. Methyl effects on protein-ligand binding J. Med. Chem. 2012, 55, 4489-4500
61. Harding, W. W.; Tidgewell, K.; Byrd, N.; Cobb, H.; Dersch, C. M.; Butelman, E. R.; Rothman, R. B.; Prisinzano, T. E. Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands J. Med. Chem. 2005, 48, 4765-4771
62. Morani, A. S.; Kivell, B.; Prisinzano, T. E.; Schenk, S. Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats Pharmacol., Biochem. Behav. 2009, 94, 244-249
63. Fantegrossi, W. E.; Kugle, K. M.; Valdes, L. J., 3rd; Koreeda, M.; Woods, J. H. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse Behav. Pharmacol. 2005, 16, 627-633
64. Butelman, E. R.; Mandau, M.; Tidgewell, K.; Prisinzano, T. E.; Yuferov, V.; Kreek, M. J. Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans J. Pharmacol. Exp. Ther. 2007, 320, 300-306
65. Simonson, B.; Morani, A. S.; Ewald, A. W.; Walker, L.; Kumar, N.; Simpson, D.; Miller, J. H.; Prisinzano, T. E.; Kivell, B. M. Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A Br. J. Pharmacol. 2014, 10.1111/bph.12692